Translational research: Forging a new cultural identity

Mount Sinai Journal of Medicine

Volumn 75, Issue 5, 2008, Pages 478-487

  Coller, Barry S ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL PRACTICE; CLOTHING; EVIDENCE BASED MEDICINE; HEALTH CARE DELIVERY; HEALTH CARE FINANCING; HEALTH CARE NEED; HEALTH CARE QUALITY; HEALTH PROMOTION; HUMAN; MEDICAL DECISION MAKING; MEDICAL EDUCATION; MEDICAL ERROR; MEDICAL ETHICS; MEDICAL RESEARCH; MOTIVATION; PHYSICIAN ATTITUDE; PROFESSIONAL STANDARD; TRANSLATIONAL RESEARCH;

BIOLOGICAL ASSAY; BIOMEDICAL RESEARCH; DRUG EVALUATION, PRECLINICAL; HUMANS; ORGANIZATIONAL CULTURE; RESEARCH; SCIENCE;

EID: 57149097087     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.20064     Document Type: Article

References (32)

1. Goldstein JL, Brown MS. The clinical investigator: bewitched, bothered, and bewildered-but still beloved. J Clin Invest 1997; 99: 2803-2812.
2. Congressional Budget Office. Research and development in the pharmaceutical industry. Available at: http://www.cbo.gov/ftpdocs/76xx/ doc7615/10-02-drugr-d.pdf. 2006; Accessed July 2008.
3. Wood AJ. A proposal for radical changes in the drug-approval process. N Engl J Med 2006; 355: 618-623.
4. Pollack, A. It's alive! Meet one of biotech's zombies. New York Times February 11, 2007.
5. Martinez B, Goldstein J. Big pharma faces grim prognosis: industry fails to find new drugs to replace wonders like Lipitor. Wall Street Journal December 6, 2007.
6. Hauser SL, McArthur JC. Saving the clinician-scientist: report of the ANA long range planning committee. Ann Neurol 2006; 60: 278-285.
7. Ley TJ, Rosenberg LE. The physician-scientist career pipeline in 2005: build it, and they will come. JAMA 2005; 294: 1343-1351.
8. Nathan DG. Clinical research: perceptions, reality, and proposed solutions. National Institutes of Health Director's Panel on Clinical Research. JAMA 1998; 280: 1427-1431.
9. Nathan DG, Schechter AN. NIH support for basic and clinical research: biomedical researcher angst in 2006. JAMA 2006; 295: 2656-2658.
10. Promoting Translational and Clinical Science: The Critical Role of Medical Schools and Teaching Hospitals. Report of the AAMCs Task Force II on Clinical Research, 1-63. Washington, DC: Association of American Medical Colleges; 2006.
11. Coller BS. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation 1995; 92: 2373-2380.
12. Coller BS. Interaction of normal, thrombasthenic, and Bernard-Soulier platelets with immobilized fibrinogen: defective platelet-fibrinogen interaction in thrombasthenia. Blood 1980; 55: 169-178.
13. Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983; 72: 325-338.
14. Seligsohn U, Mibashan RS, Rodeck CH, et al. Prenatal diagnosis of Glanzmann's thrombasthenia. Lancet 1985; 2: 1419.
15. Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet GPIIb/IIIa complex. J Clin Invest 1985; 76: 101-108.
16. Jordan RE, Wagner CL, Mascelli M, et al. Preclinical development of c7E3 Fab, a mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of GPIIb/IIIa receptors with observations on the immunogenicity of c7E3 Fab in humans. In: Horton MD, ed. Adhesion Receptors as Therapeutic Targets. Boca Raton, FL: CRC Press; 1996; 281-305.
17. Blue R, Murcia M, Karan C, et al. Application of high throughput screening to identify a novel aIIb-specific small molecule inhibitor of ℒIbβ3-mediated platelet interaction with fibrinogen. Blood 2008; 111: 1248-1256.
18. Coller BS. Monitoring platelet GPIIb/IIIa antagonist therapy. Circulation 1998; 97: 5-9.
19. Smith JW, Steinhubl SR, Lincoff AM, et al. Rapid platelet-function assay (RPFA): an automated and quantitative cartridge-based method. Circulation 1999; 99: 620-625.
20. Gold HK, Gimple L, Yasuda T, et al. Pharmacodynamic study of F(ab')2 fragments of murine monoclonal anti-body 7E3 directed against human platelet glycoprotein IIb/IIIa, in patients with unstable angina pectoris. J Clin Invest 1990; 86: 651-659.
21. Coller BS, Anderson K, Weisman HF. Inhibitors of platelet aggregation: GPIIb/IIIa antagonists. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. Update 4. Philadelphia, PA: W.B. Saunders Co. 1995; 1-10.
22. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961.
23. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation 1999; 99: 2720-2732.
24. Miles SM. The Hippocratic oath and the ethics of medicine. New York, NY: Oxford University Press; 2005.
25. Coller BS, Klotman P, Smith LG. Professing and living the oath: teaching medicine as a profession. Am J Med 2002; 112: 744-748.
26. Mohan-Ram V. 'I swear...': an oath for scientists and engineers. Science November 10, 2000.
27. Tsai DF, Chen DS. An oath for bioscientists. J Biomed Sci 2003; 10: 569-576.
28. Student Pugwash USA. SPUSA pledge. Available at: http://www.spusa.org/ pledge. Accessed July 2008.
29. National Institutes of Health. Biomedical research workforce. Available at: http://grants.nih.gov/grants/new_investigators/ workforce_info09072007.ppt. Accessed July 2008.
30. What is Pasteur? Available at: http://www.pasteur.harvard.edu. Accessed July 2008.
31. Ausiello D. Science education and communication: ANP presidential address. J Clin Invest 2007; 117: 3128-3130.
32. Snow CP. The Two Cultures. Cambridge, United Kingdom: Cambridge University Press; 1993.